[London, 31 August 2023] – With Augnito voice-driven AI transcription capabilities now integrated into the OpenRad Cloud (by Biotronics3D), its English speaking users will benefit from the increased efficiency and functionality that Augnito’s native speech reporting offers.
Scribetech today announced the successful integration of Augnito Voice Services™, an AI-powered voice-driven speech recognition API/SDK, into OpenRad Cloud (by Biotronics3D) – a remote radiology reporting platform.
OpenRad is a supplier of innovative radiology solutions for static and mobile diagnostic imaging centres worldwide, empowering healthcare professionals and the wider clinical research community with fully digitalised workflow processes that connect people, technology, and data.
Augnito is a secure and portable clinical speech recognition suite that offers medical professionals highly accurate, fast, effortless ways to dictate and transcribe live clinical data, on any mobile or desktop device – without the need for typing or outsourced services. For integrators and systems developers, Augnito delivers effective speech-enablement and voice-driven capability to many applications and clinical systems.
With the Augnito Voice Services API/SDK integrated into the cloud-based reporting platform, OpenRad can assist a severely understaffed and overworked profession with time-saving, highly accurate speech recognition technology. The combined solution means radiologists can accommodate increasing workloads and ever-expanding levels of diagnostic reporting from wherever they have an internet connection.
By speech-enabling the OpenRad Cloud reporting solution, Augnito delivers enhanced value, increased efficiency, and clinical data accuracy to OpenRad’s thousands of reporters. As well as making workloads more manageable, this also positively impacts the patient journey – from diagnosis to hospital stays – with an improved more seamless continuum of care.
OpenRad has also selected to add Augnito Spectra as a standalone “off the shelf” speech recognition product to its solution offering. The two Augnito products address multiple technology challenges previously experienced by OpenRad reporters. Many of these issues were the result of legacy non-interoperable products that are effective in isolation, but do not work so well together as one cohesive workflow.
Shiraz Austin, Managing Director at Scribetech (UK) Ltd and Co-Founder of Augnito stated: “Augnito is a disruptive innovation technology that carries Scribetech’s commitment to data accuracy along with our strong 20+ year heritage of delivering digital dictation solutions and transcription services to the NHS. It brings speech recognition to the clinical healthcare professionals who need it the most, alleviating clinical risk, cutting costs, and avoiding difficult and time-consuming upgrades on legacy systems.”
“In the UK, we look to provide Augnito speech recognition through a highly selective network of best in breed partners that share our approach to developing solutions that embrace AI innovation to enhance healthcare intelligence. OpenRad solidifies this strategy.”
“Augnito will augment the existing support and reporting benefits that our cloud-based reporting platform offers radiologists in the public and private healthcare system across the UK and English-speaking countries. This integration enables OpenRad to expand on its mission to transform healthcare through an open diagnostic network. At OpenRad we put patient outcomes first by speeding up clinical decision-making through the seamless connection and collaboration of healthcare experts, imaging providers, referrers, and their patients.” stated Brian Plackis Cheng, CEO of OpenRad.
For media enquiries, please contact [email protected]
Notes to editors
About Scribetech (UK) Ltd and Augnito
Scribetech (UK) Ltd is a clinical solutions innovator and official distributor of Augnito products in the UK and Ireland. The company co-developed Augnito with its sister company Augnito India Private Ltd fusing 20 years of highly accurate and secure transcription and digital dictation services to the NHS, speech-to-text, and clinical coding solutions for the healthcare sector, and its own Deep Neural Network speech recognition engine with advanced voice AI technology. Augnito provides a secure, cloud-based, voice-driven AI clinical speech recognition product suite, offering fast, easy ways to capture live clinical data on any device with 99% accuracy, support for multiple medical specialities, and no need for voice profile training. Augnito brings cost effective, seamless speech recognition to daily workflows and third-party clinical systems, quickly turning medical information into documentation that makes healthcare intelligence compliant and accessible where it is needed. Visit www.scribetech.co.uk for more details.
Founded in 2021 and based in London and Berlin, OpenRad delivers innovative radiology solutions for static and mobile diagnostic imaging centres worldwide. OpenRad aims to empower healthcare professionals and the wider research community by connecting people, technology, and data.
By combining the intelligent products and services of previously acquired Biotronics3D and Visbion, OpenRad can fully digitalise the workflow processes within the radiological diagnostic sphere. Its zero footprint SaaS based solutions speed up implementation, increase centre utilisation, provide remote access, and reduce cost of ownership. Visit www.openrad.com for further information.
[London, 30 June 2023] – Scribetech has been dramatically expanding its ecosystem of Augnito partnerships and successful integrations in order to empower more healthcare professionals with clinical documentation flexibility and a more efficient way of working.
Efficient clinical speech/voice-to-text digital dictation technology has the potential to improve clinical workflows, reduce delayed patient journeys and enable better informed outcomes. Such technology is only as effective as it is accessible, easy to adopt, easy to integrate, and easy to use.
To this end Scribetech (UK) Ltd, co-creator of Augnito, has invested in a new ecosystem of distributors, value added resellers and integration partners to help bring its AI-powered speech recognition technology to more users across the UK, starting with the new channel’s customers.
In the past three months, companies have been onboarded as distributors for Augnito Spectra – a cloud-based clinical speech recognition solution that supports any English accent, out of the box. This recent UK activity follows successful agreements with resellers in the last quarter. In addition, integration partners including Aptvision, OpenRad and Intelerad have recently integrated Augnito Voice Services into their own radiology reporting platforms, bringing higher levels of accuracy and the time-saving advantage of speech to the systems their respective medical customers already use.
This recent success aligns with Augnito’s sales and development team’s core strategy, reflecting not only a strong 2-year track record in delivering measurable savings and benefits to healthcare, but also reiterating the premier service-oriented heritage it carries from its co-developer’s solution support to the NHS in the last two decades.
More than 12,000 doctors across 355 hospitals and 24 partners in UK, USA, Canada, India, the Middle East and APAC, have signed up to Augnito in just 24 months. They are joined by 1500 radiologists and a growing number of consultants at various NHS Trusts. “Everything comes back to the mission we set out when we launched Augnito in the UK in late 2021,” stated Shiraz Austin, Managing Director at Scribetech (UK) Ltd and Co-Founder of Augnito.
“We know that when access to technology is simplified from the ground up, even small increases in performance turn into huge savings. Those savings can be repurposed into what matters most – making healthcare professionals efficient at delivering exceptional care and improving patient outcomes.”
Interoperability and integration are both key to this important goal. Through Augnito Voice Services and a flexible API/SDK, healthcare technology providers can integrate speech recognition into their own platforms in a matter of weeks. To date, Cimar UK, Hexarad, Fujifilm UK Medical Systems and Magentus have all integrated Augnito technology into their radiology systems, enabling efficient workflows for their customers with more accurate diagnostic reporting.
Augnito Spectra gives users constant access to accurate speech recognition and live data input on any device running either Windows or MAC operating systems. This data is then routed securely to clinical systems including PACS and EPRs. Augnito’s ability to fit into existing clinical workflows makes user adoption easier and effective. It reduces both workload management and costs, as well as changing the way providers deploy new technology – ground up vs. top down.
Austin added: “Through our best-in-breed partnerships, we’re introducing real product flexibility and agility to assist medical health professionals in providing better patient journeys. We’ve been proactive in creating more ways to use Augnito, helping us align to the NHS plan for digital transformation and ensure new technology is integrated in a way that will naturally drive user adoption.”
For IT and technology providers in healthcare, Augnito Spectra carries a compelling (up to) 30% profit margin on every UK licence the partner sells. It is designed to be easy and fast to deploy and looks to complement partners’ existing product portfolios and service offerings. For partners’ users, Augnito Spectra provides simpler and more accurate clinical data input into all major EPR systems.
Austin concluded: “We’ve seen significant demand from resellers because the demand is there across healthcare. Inefficiencies and reporting bottlenecks are costing millions of pounds in Delayed Transfer of Care (DTOC) and bed costs as well as the ever growing patient waiting lists. And with rising demand and intense workloads, everyone inside a Trust knows something needs to change. The healthcare user benefits and the time and financial savings are significant from day one. In fact the cost of Augnito per day is less than a takeaway coffee.”
Notes to editors
About Augnito and Scribetech
Augnito is a secure, cloud-based, AI-driven clinical speech recognition product suite. It offers fast, easy ways to capture live clinical data on any device with 99% accuracy, support for multiple medical specialities, and no need for voice profile training. Augnito brings seamless speech recognition to daily workflows and third-party clinical systems, turning medical information into clinical documentation and making healthcare intelligence securely accessible everywhere.
Augnito was co-developed by Scribetech, a clinical voice solutions innovator, fusing 20 years of transcription and digital dictation services to the NHS, speech-to-text, and clinical coding solutions for the healthcare sector, and its own speech recognition engine with advanced voice AI technology.
[London, 18 May 2023] – Augnito Voice Services™ will integrate with Intelerad’s InSight PACS reporting, equipping clients with accessible, advanced speech recognition technology that simplifies patient care.
This new integration partnership will provide Intelerad clients with increased voice recognition options, giving them access to a pioneering, cloud-based product that helps ensure clients are not limited to one voice recognition platform and the risks associated with that dependence.
Intelerad Cloud is a menu of expertly cloud-engineered solutions designed to optimise the benefits of Cloud technology and scalability potential without sacrificing the performance of onsite architecture. Proudly vendor-neutral, Intelerad, is integrating its products with multiple technologies which fit with its cloud-based strategy, Augnito being the most recent. These can assist with the Cloud First strategy by utilising the Cloud for disaster recovery, image exchange and long-term archiving, and this latest addition is another way Intelerad is providing the latest cloud innovations and future resilience required by its clients.
Augnito can be used with a speech microphone or even through an app on a smartphone, making it faster and easier for radiologists and clinicians to diagnose critical conditions where every second counts, leading to better outcomes for patients.
Shiraz Austin, Managing Director at Scribetech (UK) Ltd and Co-Founder of Augnito stated, “Intelerad is a best-in-class provider of medical imaging software with a mission statement that dovetails very well into our own – where technology is developed to impact healthcare in a positive way and where making more time for patient care is paramount. Our partnership agreement solidifies the solution strategies of both organisations, and we’re excited that our secure, cloud-based, voice-powered AI speech recognition technology, Augnito, will play an important role in achieving this. Through the use of Augnito technology, Intelerad can empower radiologists to deliver reporting when and where it’s needed to keep the patient journey and clinical workflows moving.”
Intelerad is exploring integrating Augnito into other products in its portfolio, Arron Edwards, Managing Director of Intelerad, commented, “Intelerad is excited to be able to add the class-leading, cloud-based speech engine from Augnito into our fully featured rich reporting solution, which is built into InSight PACS. Our UK engineering team have worked hand-in-hand with the Augnito engineering team at Scribetech, leading to an incredibly successful integration which will ensure that we can continue to offer a best-in-class solution for our clients.”
For further information, please contact:
Clare Dawe, Marketing Manager, Insignia Medical Systems powered by Intelerad
01256 247 010
Intelerad is one of the leading providers of medical imaging software and services for the healthcare industry. Headquartered in Raleigh, NC and Montreal, Quebec, Intelerad has over 900 employees located in offices across six countries. Nearly 2,500 healthcare organizations around the world rely on Intelerad products to manage patient data, helping them reduce time and workload while improving patient outcomes. Intelerad’s award-winning enterprise imaging solutions have been recognized globally by KLAS, with Intelerad’s Ambra Health ranked #1 in Image Exchange for eight consecutive years. To learn more, visit intelerad.com.
Intelerad welcomes contact from PRs and journalists for quotes, expert opinions or bespoke content for particular press articles. Please contact Clare Dawe in the first instance at [email protected]
ABOUT SCRIBETECH AND THE AUGNITO SOLUTION
Augnito is a secure, cloud-based, AI-driven clinical speech recognition product suite. It offers fast, easy ways to capture live clinical data on any device with 99.3% accuracy, support for multiple medical specialties, and no need for voice profile training. Augnito brings seamless speech recognition to daily workflows and third-party clinical systems, turning medical information into clinical documentation and making healthcare intelligence securely accessible wherever it’s needed. Augnito was co-developed by Scribetech, a clinical voice solutions innovator, fusing 20 years of transcription and digital dictation services to the NHS, speech-to-text, and clinical coding solutions for the healthcare sector, and its own speech recognition engine with advanced voice AI technology. Follow us on Linked-In.
[London, 29 March 2023] – With the NHS struggling to meet the demands of an ageing population, complex discharge processes, and widespread bed shortages, new technology has an important role to play in safeguarding patient outcomes.
The past few years have been incredibly challenging for the NHS, with the pandemic and heightened demand bringing longstanding problems into sharp, urgent focus. Bed shortages continue to be a major issue, with British Medical Association data from December 2022 reporting that occupancy rates consistently exceed safe levels. Meanwhile, Delayed Transfers of Care (DTOCs) create unnecessary bottlenecks, with patients occupying beds when they are clinically ready to be discharged or transferred.
For NHS Trusts, this creates a significant, largely unnecessary cost – one that’s hard to immediately address by adding new bed stocks. That’s why Scribetech, the co-creators of AI speech recognition solution Augnito, are working to help Trusts understand the potential of innovative new technology.
“For decades, the NHS has tried to address bed stock and occupancy issues by adding more beds, but we have consistently seen that it’s almost impossible to keep up with demand” stated Shiraz Austin, Managing Director at Scribetech and Co-Founder of Augnito. “Technology and changes in ways of working have the potential to reduce occupancy rates and improve care in a way that’s more sustainable. But this transformation is only possible if it makes financial sense.”
Estimating the financial cost of DTOCs and the bed shortage is difficult. Department of Health figures put the cost of a DTOC bed at £400/day, while Age UK report 2019 costs of £346/day. Using a forgiving cost of £350/day, this implies a bill in excess of £54 million just for the delayed days in February 2020, when DTOC metrics were last reported.
Speech recognition technology like Augnito can’t immediately eliminate all DTOCs, but it can deliver consistent, incremental improvements to the workflows of multidisciplinary teams (MDTs). With real time dictation and transcription in any platform or dedicated desktop and smartphone applications, healthcare professionals can reduce the risk of delays arising from inaccurate records, lost records, and breakdowns in communication.
Austin continued: “The financial outlook is clear: the cost of new technology is significantly less than the cost of delays and low bed stocks. The cost of a single extra bed per day is 10 times the cost of an Augnito licence for a month. But that commercial reality is just one part of the picture. There’s a human cost that must also be considered.”
While delays and occupied beds affect every patient – and, indeed, the entire healthcare system including social care – some particularly vulnerable groups are disproportionately affected. December 2021 saw intensive care beds for children reach record occupancy of 89% across the country. Meanwhile, older patients are particularly at risk given the typical complexity of their discharge or transfer to other providers.
When paediatric beds simply aren’t available or elderly patients are kept on wards for weeks, even months after they’re ready to be transferred, their experience is resoundingly negative. They’re unable to receive the care that is appropriate, when it is required, in the right setting. In some cases, this comes with a very real and measurable impact on outcomes.
Austin concluded: “Augnito is designed to work for NHS Trusts – a cloud-hosted technology that’s significantly lower in cost than unnecessary delays and can be implemented quickly and easily. But it’s also designed to empower healthcare professionals and multidisciplinary teams to work efficiently, so they can act based on what patients need, without being limited by processes and old, outdated workflows.”
Notes to editors
Full blog posts referenced in this media alert:
For further information, interview opportunities or accompanying graphics please contact: [email protected]
About Scribetech and the Augnito solution – visit https://www.scribetech.co.uk/ for details and follow us on Linked-In.
Augnito is a secure, cloud-based, AI-driven clinical speech recognition product suite. It offers fast, easy ways to capture live clinical data on any device with 99.3% accuracy, support for multiple medical specialities, and no need for voice profile training. Augnito brings seamless speech recognition to daily workflows and third-party clinical systems, turning medical information into clinical documentation and making healthcare intelligence securely accessible wherever it’s needed. Augnito was co-developed by Scribetech, a clinical voice solutions innovator, fusing 20 years of transcription and digital dictation services to the NHS, speech-to-text, and clinical coding solutions for the healthcare sector, and its own speech recognition engine with advanced voice AI technology.
[London, 10 February 2023] – As the NHS continues to address and reduce Delayed Transfer of Care (DTOC) incidents – and their associated costs – speech recognition has the potential to deliver transformative efficiency gains.
With the healthcare system under unprecedented pressure, NHS Trusts are reflecting on key metrics associated with performance, cost, and quality of patient care. Delayed Transfers of Care (DTOCs) see patients continue to occupy beds when they are clinically ready to be transferred or discharged. This results in significant expense to the NHS, a lack of available bed stocks, and disrupted journeys for both the patients waiting for transfer and those waiting for beds.
According to Scribetech, UK distributors of Augnito, a cloud-based, AI-powered speech recognition solution, new technology and workflow transformation have the potential to significantly improve how DTOC is managed.
“DTOCs are an indicator of how healthy the health and social care systems are,” stated Shiraz Austin, Managing Director at Scribetech (UK) Ltd and Co-Founder of Augnito.ai. “When patients continue to occupy beds they don’t clinically need, there’s a ripple effect that stretches across the patient journey. This includes delays to treatment for new patients, as well as a considerable amount of distress for those needlessly held in hospital.”
The scale of the DTOC problem is significant. In February 2020, reports show, there were an average of 5370 people delayed per day across the NHS in England – some attributable to the NHS, some attributable to social care, and some with joint responsibility. Based on the Department of Health’s reported costs of an excess bed per day (£350 – £400), the estimated cost of DTOC was as high as £2,148,000 per day for that month alone.
However, this immediate financial impact is just one consequence of DTOCs. With bed stocks at an all-time low and occupancy at an all-time high, DTOCs directly affect the availability of treatment, making acute care when a bed is finally available even more costly and negatively affecting patient outcomes.
Innovative new technology has the potential to positively influence these outcomes – but Austin remains realistic about the results.
Austin continued: “It’s not that technology like Augnito can solve the DTOC challenge overnight. It’s that incremental improvements to the way healthcare professionals work, collaborate, and share information eliminate the low-hanging fruit of slow reporting and typing into cumbersome, often outdated, systems. And time saved leads to reduced cost, where budgets can be repurposed into wider, systemic changes.”
Augnito was designed in partnership with healthcare professionals to address their biggest challenges. This includes bringing real-time SR to the clinical systems used as part of the discharge and transfer process, allowing people to work faster and more flexibly.
Adopted widely, Augnito can deliver:
– Faster reporting time and fewer internal delays to patient discharge or transfer
– Reduced costs, which can be repurposed into growing bed stocks and community nursing
– Increased bed availability with less waste and lower occupancy
– A way to offset the removal of the Government’s Covid-19 DTOC funding
As standard, Augnito empowers healthcare professionals with advanced SR on any device – desktops, web browsers, and mobiles. With a flexible SDK and API, Augnito can also be integrated into existing systems for accurate, immediate capture into an Electronic Patient Record.
Based on February 2020 DTOC data, just a small reduction in turnaround time, inaccuracies and errors could save the NHS hundreds of thousands per month. Austin concluded: “Augnito creates a more seamless way of working for healthcare professionals, helping with considerable workloads and backlogs. But its real impact is on the NHS as a whole, improving financial drainage and removing the bottlenecks that become obstacles to outstanding patient care and the best possible outcomes.”
Notes to editors
Read the full blog post here www.scribetech.co.uk/2023/01/31/can-the-advantages-of-clinical-voice-ai-sr-technology-help-reduce-dtoc
For further information, interview opportunities or accompanying graphics please contact: [email protected]
About Augnito India Private Limited – visit Augnito.ai.
[London, 31 January 2023] – Scribetech has been re-appointed to the NHS Commercial Solutions Framework Agreement for the provision of digital dictation, speech/voice recognition, outsourced transcription and associated services in all four of the authority’s lots.
Scribetech (UK) Ltd has been re-awarded its third consecutive listing, since 2010, on the NHS Commercial Solutions Framework following the contracting authority’s comprehensive information gathering and tender evaluation process.
Scribetech will see its Textflow digital dictation solution and Augnito voice-AI speech recognition products offered to all NHS organisations.
The four lots under the NHS Commercial Solution framework agreement for which a product or services provider is invited to tender include: Products and/or Services Catalogue; In-house and Outsourced Digital Dictation Service Solution, Outsourced Transcription Service Solution, and Managed Service Solution.
Formed in 2007, and based in the South East of England, the NHS Commercial Solution Framework is a non-profit procurement shared services hub providing collaborative solutions and end-to-end services that combine data analytics and its dedicated category specialists’ in-depth knowledge of supply markets to address stakeholder needs. Categories include: corporate services, digital, estate and facilities, pharmacy, workforce and staffing, and clinical. These services are offered and provided across the NHS and the wider public sector, supporting acute, mental health, community, ambulance trusts, and commissioning organisations.
To date, NHS Commercial Solutions has saved in excess of £230 million for its customers, based on year one project savings alone.
Scribetech has long been recognised as a pioneering clinical transcription services and medical documentation company that has consistently ranked top on multiple NHS Framework contracts since 2005. “We are extremely pleased with the NHS Commercial Solutions award. It validates not only Scribetech’s vision and our digital dictation technology and voice-AI capabilities, but the ability to provide NHS organisations with cost-effective solutions that really do address many of the core issues that confront medical professionals on the healthcare frontline, such as improving efficiency and accuracy, as well as optimising clinical workflows, resources and budgets.” commented Shiraz Austin, Co-Founder of Augnito and Managing Director at Scribetech (UK) Ltd.
“Scribetech was founded to provide acutely accurate, efficient, cost-effective, outsourced and in-house services and technology to support NHS clinical transcription. Augnito was developed as a result of 20 years of hands-on-experience delivering such services. Combining our digital dictation, transcription and speech recognition voice-AI offering as an augmented clinical administration solution is where we believe NHS organisations will start to see their digital transformation garnering the positive results they critically need across all care departments” concluded Austin.
Notes to editors
For further information, interview opportunities or accompanying graphics please contact: [email protected]
About Scribetech Textflow and Augnito
Visit https://www.scribetech.co.uk/ for more details.